J&J trims neuroscience pipeline – seltorexant in Alzheimer’s disease dropped
J&J has cut two Phase II programmes and one Phase I asset in its neuroscience portfolio.
J&J has cut two Phase II programmes and one Phase I asset in its neuroscience portfolio.
What's Your Reaction?
